CLLS250117P5000
- 0.00
- 0.000.00%
Cellectis Newsroom
Citi Maintains Cellectis(CLLS.US) With Buy Rating, Cuts Target Price to $11
Promising Partnership and Pipeline Propel Cellectis SA to a Buy Rating
Barclays Maintains Cellectis(CLLS.US) With Buy Rating, Maintains Target Price $5
JMP Securities Maintains Cellectis(CLLS.US) With Buy Rating, Maintains Target Price $6
Cellectis Is Maintained at Overweight by Barclays
Cellectis Analyst Ratings
Barclays Maintains Cellectis(CLLS.US) With Buy Rating, Cuts Target Price to $5
Cellectis SA: Strong Buy Rating on Robust Pipeline and Financial Stability
Barclays Maintains Cellectis(CLLS.US) With Buy Rating, Maintains Target Price $7
Cellectis Analyst Ratings
Cellectis Analyst Ratings
JMP Securities Reiterates Market Outperform on Cellectis, Maintains $6 Price Target
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Cellectis SA (CLLS) and Sanofi (OtherSNYNF)
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Fortrea Holdings Inc. (FTRE) and Cellectis SA (CLLS)
Analysts Offer Insights on Healthcare Companies: Ardelyx (ARDX), Oric Pharmaceuticals (ORIC) and Cellectis SA (CLLS)
Cellectis SA: Strong Investment and Clinical Progress Signaling a Market Outperform Rating
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Cellectis SA (CLLS) and Idexx Laboratories (IDXX)
Barclays Remains a Buy on Cellectis SA (CLLS)
Cellectis SA: A Hold Rating Amidst Strategic Partnerships and Pipeline Potential
Hold Rating for Cellectis SA: A Balance of Promising Data and Pending Uncertainties